Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs

Introduction

Introduction

It’s time to click on this.

The media’s dubbed them ‘a doctor in your pocket’ and ‘health care helpers’. Yet despite the explosion of mobile apps in other industries, pharma has generally been slow to exploit the possibilities they represent. What are the hurdles facing the industry and who are the leaders overcoming them? How can companies develop a mHealth approach that both addresses end-user needs and key messaging? What does pharma need to know about regulatory and legal hurdles?

Concisely written and expertly researched, this FirstWord Dossier report succinctly addresses the issues surrounding the emerging mHealth industry—and finds the answers.

Scope

Report Overview

Offering a compelling case for pharma to firmly establish its voice in mHealth, the report contains detailed insight into the opportunities app development represents. Encompassing the full range of questions demanded by the industry, the report includes expert insight from both those in pharma currently working ahead of the curve and mHealth developers themselves.

Whether your company is looking to expand into mHealth apps or seeking sound advice on a way forward, Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs has the answers.

Highlights

Key Report Features

Puchase Reasons

Key Benefits

Key Questions Answered

Who Should Read This Report

Expert Views Include:

Dr. Dave Albert, Co-founder and Chief Medical Officer, AliveCor

Orion Armon, Partner, Cooley LLP

Kenneth Bennett, Senior Director, IS Business Partner, Sanofi US division

Lena Feygin, Managing Director, WeMultiply

Shwen Gwee, Vice President, Digital Health, Edelman

Peter Justason, Director, eMarketing, Purdue Pharma

Duncan Learmouth, Senior Vice President, Developing Countries & Market Access, GlaxoSmithKline

Jonathan Martin, Director of Education and Awareness Programs, National Marfan Foundation

Dr. Patricia Mechael, Executive Director, mHealth Alliance

Brian Meltzer, Executive Director, R&D Innovation, Purdue Pharma

Dr. Satish Misra, Managing Editor, iMedicalApps and member, Steering Committee, Johns Hopkins Global mHealth Initiative

Scott Morrison, Vice President, Information Systems, Boehringer Ingelheim

Judy Wade, ex-CEO, AliveCor

Key Quotes

“The business case for pharma to engage in mHealth makes a lot of sense. But pharma has been quite slow to really embrace things in mobile health in a strategic or systematic way.” Dr. Patricia Mechael, executive director, mHealth Alliance

“There is substantial opportunity for pharmaceutical companies to be involved; it’s just that they have to walk that fine line between providing a service to the patient population and having what they’re doing viewed as just a kind of marketing. As soon as it gets perceived as the latter, all the alarm bells will go off.” Dr. Satish Misra, managing editor, iMedicalApps

Table of Contents
for Pharma and the mHealth Revolution - engaging with mobile-enabled physicians and HCPs

• 1.Executive summary

  2.Introduction

  3.Possibilities

  3.1. On the go

  3.2. Device ownership

  3.3. Medical practice has changed

  3.4. Using mHealth devices

  3.5. Topic diversity

  3.6. Global diversity

  4.Realities

  4.1.The pioneers

  4.2. Rules of engagement

  4.3. Phone or web?

  5.Pharma’s role in mHealth - Five detailed examples

  5.1. Eli Lilly: Glucagon mobile app

  5.2. AstraZeneca: EGFR mutation test

  5.3. Johnson & Johnson: BlackBag

  5.4. AliveCor: Heart monitor

  5.5. GlaxoSmithKline: Mozambique vaccines programme

  6.Case Study

  6.1. Sanofi’s mHealth strategy

  6.2. A variety of offerings

  6.3. The bottom line

  7.Uncertainties

  7.1. Regulators weighing options

  7.2. A Congressional approach

  7.3. Intellectual property concerns

  7.4. User hesitancy

  8.What’s ahead?

  8.1. Predicted growth

  8.2. Emerging technology

  8.3. Listening to the users

  8.4. Assuring efficacy

  8.5. The final requirement: Patience

  9. Acknowledgements

Additional Details

Publisher

FirstWord Pharma

Publisher Information

Reference

37 |

Number of Pages

83

Report Format

PDF

Related Reports